NCT00775840 - Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Heart Failure

Interventions

DRUG

Candesartan

Candesartan up to 32 mg, tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.

DRUG

Placebo

Candesartan matching-placebo tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.

Trial Locations (37)

Unknown

Bad Friedrichshall

Heidelberg

Ludwigsburg

Bad Homburg

Bad Nauheim

Darmstadt

Frankfurt am Main

Giessen

Kassel

Limburg an der Lahn

Melsungen

Mühlheim am Main

Wiesbaden

Nienburg

Northeim

Weyhe

Essen

Gelsenkirchen

Gladbeck

Langenfeld

Paderborn

Siegen

Bad Kreuznach

Neukirchen

Dresden

Hartmannsdorf

Leipzig

Leisnig

Machem

Markkleeberg

Riesa

Wermsdorf

Coswig

Berlin

Erfurt

Jena

Nordhausen